Barclays’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-14,400
| Closed | -$49K | – | 7691 |
|
|
2018
Q3 | $49K | Sell |
14,400
-2,900
| -17% | -$10.5K | ﹤0.01% | 6097 |
|
|
2018
Q2 | $65K | Buy |
17,300
+5,100
| +42% | +$24.8K | ﹤0.01% | 5508 |
|
|
2018
Q1 | $50K | Buy |
12,200
+7,600
| +165% | +$35.4K | ﹤0.01% | 5912 |
|
|
2017
Q4 | $21K | Sell |
4,600
-7,600
| -62% | -$41.9K | ﹤0.01% | 6282 |
|
|
2017
Q3 | $87K | Buy |
12,200
+800
| +7% | +$5.75K | ﹤0.01% | 5023 |
|
|
2017
Q2 | $82K | Buy |
11,400
+5,800
| +104% | +$36.2K | ﹤0.01% | 5061 |
|
|
2017
Q1 | $34K | Sell |
5,600
-47,700
| -89% | -$261K | ﹤0.01% | 5556 |
|
|
2016
Q4 | $312K | Buy |
53,300
+1,900
| +4% | +$10.4K | ﹤0.01% | 3803 |
|
|
2016
Q3 | $273K | Sell |
51,400
-5,100
| -9% | -$27.5K | ﹤0.01% | 3707 |
|
|
2016
Q2 | $374K | Sell |
56,500
-26,200
| -32% | -$146K | ﹤0.01% | 3449 |
|
|
2016
Q1 | $331K | Sell |
82,700
-3,700
| -4% | -$14.8K | ﹤0.01% | 3480 |
|
|
2015
Q4 | $432K | Buy |
86,400
+42,000
| +95% | +$200K | ﹤0.01% | 3321 |
|
|
2015
Q3 | $133K | Sell |
44,400
-29,900
| -40% | -$200K | ﹤0.01% | 4433 |
|
|
2015
Q2 | $669K | Buy |
74,300
+38,900
| +110% | +$417K | ﹤0.01% | 3233 |
|
|
2015
Q1 | $425K | Sell |
35,400
-71,300
| -67% | -$917K | ﹤0.01% | 3750 |
|
|
2014
Q4 | $1.49M | Sell |
106,700
-116,100
| -52% | -$1.8M | ﹤0.01% | 2800 |
|
|
2014
Q3 | $2.9M | Buy |
222,800
+54,000
| +32% | +$827K | ﹤0.01% | 2322 |
|
|
2014
Q2 | $2.53M | Sell |
168,800
-96,200
| -36% | -$1.36M | ﹤0.01% | 2365 |
|
|
2014
Q1 | $4.5M | Buy |
265,000
+170,000
| +179% | +$2.56M | 0.01% | 1765 |
|
|
2013
Q4 | $1.14M | Buy |
95,000
+61,000
| +179% | +$728K | ﹤0.01% | 3253 |
|
|
2013
Q3 | $340K | Sell |
34,000
-36,800
| -52% | -$327K | ﹤0.01% | 4518 |
|
|
2013
Q2 | $529K | Buy |
+70,800
| New | +$553K | ﹤0.01% | 4139 |
|
Barclays's KERX Position: Q4 2018 in Review
Barclays sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 259,160 shares — an estimated $881K sold.
Barclays first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $970K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Barclays reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Barclays sold 259,160 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $881K.
- Barclays first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Barclays's Keryx Biopharmaceuticals Inc position peaked at $970K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.